Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
Am J Epidemiol ; 154(7): 610-7, 2001 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-11581094

RESUMO

A case-control study was conducted among 205 women in Michigan and Ohio who were diagnosed with undifferentiated connective tissue disease (UCTD) to investigate the significance of self-reported past exposures to implanted silicone-containing or non-silicone-containing medical devices. The 205 UCTD cases were compared with 2,095 controls who were sampled by random digit dialing. When silicone-containing devices, including shunts and catheters, were analyzed collectively, a significant association was observed (odds ratio (OR) = 2.81, 95% confidence interval (CI): 1.34, 5.89). The odds ratio for exposure to breast implants was increased, but not significantly (OR = 2.22, 95% CI: 0.65, 7.57). Among the non-silicone-containing devices, artificial joints (OR = 5.01, 95% CI: 1.60, 15.71) and orthopedic metallic fixation devices (OR = 1.95, 95% CI: 1.05, 3.60) were associated with UCTD. The estimations of risk associated with implanted medical devices in UCTD cases were explored in a comparison with 660 scleroderma patients who were ascertained concurrently in Michigan and Ohio. In general, the associations that were observed with non-silicone-containing devices, and more specifically with the fixation devices, persisted in the comparison of UCTD cases with scleroderma patients. The studies conducted among populations in Michigan and Ohio are intended to stimulate new hypotheses, innovative approaches, and the fostering of understanding of the environmental determinants of autoimmune disease.


Assuntos
Doenças do Tecido Conjuntivo/etiologia , Próteses e Implantes/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Implantes de Mama/efeitos adversos , Estudos de Casos e Controles , Doenças do Tecido Conjuntivo/epidemiologia , Feminino , Humanos , Prótese Articular/efeitos adversos , Michigan/epidemiologia , Pessoa de Meia-Idade , Razão de Chances , Ohio/epidemiologia , Dispositivos de Fixação Ortopédica/efeitos adversos , Fatores de Risco , Escleroderma Sistêmico/etiologia , Silicones/efeitos adversos
2.
Am J Respir Crit Care Med ; 164(4): 536-41, 2001 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-11520711

RESUMO

An association has been reported between chronic infection with Chlamydia pneumoniae and the severity of asthma, and uncontrolled observations have suggested that treatment with antibiotics active against C. pneumoniae leads to an improvement in asthma control. We studied the effect of roxithromycin in subjects with asthma and immunoglobulin G (IgG) antibodies to C. pneumoniae > or = 1:64 and/or IgA antibodies > or = 1:16. A total of 232 subjects, from Australia, New Zealand, Italy, or Argentina, were randomized to 6 wk of treatment with roxithromycin 150 mg twice a day or placebo. At the end of 6 wk, the increase from baseline in evening peak expiratory flow (PEF) was 15 L/min with roxithromycin and 3 L/min with placebo (p = 0.02). With morning PEF, the increase was 14 L/min with roxithromycin and 8 L/min with placebo (NS). In the Australasian population, the increase in morning PEF was 18 L/min and 4 L/min, respectively (p = 0.04). At 3 mo and 6 mo after the end of treatment, differences between the two groups were smaller and not significant. Six weeks of treatment with roxithromycin led to improvements in asthma control but the benefit was not sustained. Further studies are necessary to determine whether the lack of sustained benefit is due to failure to eradicate C. pneumoniae.


Assuntos
Antibacterianos/uso terapêutico , Asma/microbiologia , Infecções por Chlamydophila/complicações , Infecções por Chlamydophila/tratamento farmacológico , Chlamydophila pneumoniae , Pneumonia Bacteriana/complicações , Pneumonia Bacteriana/tratamento farmacológico , Roxitromicina/uso terapêutico , Adulto , Antibacterianos/farmacologia , Anticorpos Antibacterianos/sangue , Asma/classificação , Asma/diagnóstico , Asma/fisiopatologia , Infecções por Chlamydophila/sangue , Infecções por Chlamydophila/diagnóstico , Infecções por Chlamydophila/imunologia , Chlamydophila pneumoniae/imunologia , Doença Crônica , Método Duplo-Cego , Feminino , Seguimentos , Volume Expiratório Forçado/efeitos dos fármacos , Humanos , Imunoglobulina G/imunologia , Masculino , Pessoa de Meia-Idade , Pico do Fluxo Expiratório/efeitos dos fármacos , Pneumonia Bacteriana/sangue , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/imunologia , Roxitromicina/farmacologia , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento
3.
J Low Genit Tract Dis ; 5(1): 48-50, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17043562

RESUMO

OBJECTIVE: Metastases to the vulva are infrequent, accounting for less than 10% of vulvar tumors. Vulvar metastases from lung carcinoma have been reported in two other cases. METHODS: A case of lung carcinoma metastatic to the vulva is reported. RESULTS: A 71-year-old woman was referred to The University of Iowa Hospitals and Clinics with a lung nodule on chest x-ray and a 12-cm, necrotic, left vulvar mass. A lung biopsy showed poorly differentiated carcinoma, and a palliative resection of the vulvar mass showed metastatic lung carcinoma. The patient died from sepsis on postoperative day 10. CONCLUSIONS: Lung carcinoma metastatic to the vulva is rare and portends a poor prognosis.

4.
Eur Respir J ; 15(2): 254-9, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10706488

RESUMO

There is evidence that infection with Chlamydia pneumoniae is associated with asthma of recent onset and that it can influence the severity of asthma. This has led to the suggestion that macrolide antibiotics may be useful in the treatment of asthma in subjects infected with C. pneumoniae. This study examined the association between immunoglobulin (Ig)G and IgA titres to C. pneumoniae and the severity of asthma. IgG and IgA antibodies to C. pneumoniae were measured in 619 subjects with asthma (18-60 yrs), using the microimmunofluoresence method. Subjects were asked about their use of asthma medicines, symptoms, previous hospitalization for asthma, smoking status and age of onset of asthma. In subjects with IgG titres of > or =1:64 and/or IgA titres > or =1:16 (n=212), spirometry was performed and peak expiratory flow rate (PEFR) and symptoms were recorded twice daily for 4 weeks on a diary card. The use of high dose inhaled steroids was associated with an increase of 74.1% in the titre of IgG antibodies (p=0.04) and an increase of 70.6% in the titre of IgA antibodies (p=0.0001) when compared with the use of low dose inhaled steroids. There was an inverse association between IgG antibodies and forced expiratory volume in one second (FEV1) as a percentage of predicted in those subjects with elevated IgG and/or IgA (p=0.04). In this group IgA antibodies were also associated with a higher daytime symptom score (p=0.04). Higher titres of antibodies to Chlamydia pneumoniae appears to be associated with markers of asthma severity. This raises the possibility that chronic infection with Chlamydia pneumoniae leads to an increase in the severity of asthma. Studies aimed at eradicating chronic infection with Chlamydia pneumoniae are necessary to determine whether or not this is the case.


Assuntos
Asma/complicações , Infecções por Chlamydia/complicações , Chlamydophila pneumoniae , Administração por Inalação , Adulto , Asma/microbiologia , Beclometasona/administração & dosagem , Infecções por Chlamydia/tratamento farmacológico , Infecções por Chlamydia/imunologia , Chlamydophila pneumoniae/imunologia , Método Duplo-Cego , Feminino , Glucocorticoides/administração & dosagem , Humanos , Imunoglobulina A/imunologia , Imunoglobulina G/imunologia , Modelos Logísticos , Masculino , Índice de Gravidade de Doença
5.
Am J Epidemiol ; 149(8): 761-70, 1999 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-10206626

RESUMO

Occupational solvent exposure may increase the risk of connective tissue disease (CTD). The objective of this case-control study was to investigate the relation between undifferentiated connective tissue disease (UCTD) and solvent exposure in Michigan and Ohio. Women were considered to have UCTD if they did not meet the American College of Rheumatology classification criteria for any CTD but had at least two documented signs, symptoms, or laboratory abnormalities suggestive of a CTD. Detailed information on solvent exposure was ascertained from 205 cases, diagnosed between 1980 and 1992, and 2,095 population-based controls. Age-adjusted odds ratios (OR) and 95 percent confidence intervals (CI) were calculated for all exposures. Among 16 self-reported occupational activities with potential solvent exposure, furniture refinishing (OR = 9.73, 95 percent CI 1.48-63.90), perfume, cosmetic, or drug manufacturing (OR = 7.71, 95 percent CI 2.24-26.56), rubber product manufacturing (OR = 4.70, 95 percent CI 1.75-12.61), work in a medical diagnostic or pathology laboratory (OR = 4.52, 95 percent CI 2.27-8.97), and painting or paint manufacturing (OR = 2.87, 95 percent CI 1.06-7.76) were significantly associated with UCTD. After expert review of self-reported exposure to ten specific solvents, paint thinners or removers (OR = 2.73, 95 percent CI 1.80-4.16) and mineral spirits (OR = 1.81, 95 percent CI 1.09-3.02) were associated with UCTD. These results suggest that exposure to petroleum distillates increases the risk of developing UCTD.


Assuntos
Poluentes Ocupacionais do Ar/efeitos adversos , Doenças do Tecido Conjuntivo/induzido quimicamente , Doenças Profissionais/induzido quimicamente , Petróleo/efeitos adversos , Solventes/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças do Tecido Conjuntivo/epidemiologia , Feminino , Humanos , Michigan , Pessoa de Meia-Idade , Doenças Profissionais/epidemiologia , Ohio , Fatores de Risco
7.
8.
Arthritis Rheum ; 40(4): 734-42, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9125258

RESUMO

OBJECTIVE: To examine racial differences in disease onset, extent, manifestations, and survival among women with scleroderma. METHODS: A retrospective cohort study of women with scleroderma, diagnosed in Michigan between 1980 and 1991, was conducted. Clinical, laboratory, and demographic data were abstracted from the patients' medical records. RESULTS: A total of 514 women with scleroderma were identified: 117 (23%) were black and 397 (77%) were white. Among black women, the mean age at diagnosis was lower (44.5 years versus 51.5 years; P < 0.001) and diffuse disease was more common (49.6% versus 24.9%; P < 0.001) than among white women. The overall incidence of scleroderma was 14.1 per million per year: 22.5 per million per year in black women versus 12.8 per million per year in white women (P < 0.001). Pericarditis (P = 0.009), pulmonary hypertension (P < 0.001), pleural effusions (P = 0.01), myositis (P = 0.02), and an erythrocyte sedimentation rate >40 mm/hour (P < 0.001) were more frequent among black women, while white women were more likely to have digital infarctions (P < 0.001). Survival at 7 years from diagnosis was 72.5% among black women and 77.6% among white women. Age-adjusted survival was significantly reduced among black women (P = 0.033), most likely because of increased diffuse involvement. Survival among those with renal or pulmonary involvement was also significantly reduced. CONCLUSION: Black women with scleroderma were significantly more likely than white women to develop diffuse disease, be diagnosed at a younger age, have a higher incidence of inflammatory features, and have a worse age-adjusted survival rate.


Assuntos
População Negra , Escleroderma Sistêmico/etnologia , População Branca , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Humanos , Michigan/epidemiologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Escleroderma Sistêmico/mortalidade , Análise de Sobrevida
9.
Artigo em Inglês | MEDLINE | ID: mdl-9007931

RESUMO

Temporomandibular disorders (TMDs) can affect the form and function of the temporomandibular joint, masticatory muscles, and dental apparatus. Electronic measurement of mandibular movement and masticatory muscle function provides objective data that are defined by commonly accepted parameters in patients with TMDs; these data can then be used to design and monitor therapy and enhance treatment therapy. In this study, data on 3681 patients with TMD are presented, including electronic test data on 1182 treated patients with TMDs. Electronic jaw tracking was used to record mandibular movement and to compare the presenting and therapeutic dental occlusal positions. Electromyography was used to analyze the resting status of masticatory muscles and occlusal function at presentation and after therapeutic intervention. Transcutaneous electrical nerve stimulation therapy relaxed masticatory muscles and aided in the determination of a therapeutic occlusal position. The data show a positive correlation between the clinical symptoms of TMD and the presenting occlusion, accompanied by muscle activity. A strong positive correlation also appears to exist between a therapeutic change in the dental occlusion to a neuromuscularly healthy position with use of a precision orthotic appliance and the significant relief of symptoms within 1 month and at 3 months.


Assuntos
Registro da Relação Maxilomandibular/instrumentação , Transtornos da Articulação Temporomandibular/diagnóstico , Transtornos da Articulação Temporomandibular/terapia , Estimulação Elétrica Nervosa Transcutânea , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Eletromiografia , Feminino , Humanos , Masculino , Má Oclusão/complicações , Má Oclusão/terapia , Mandíbula/fisiologia , Músculos da Mastigação/fisiopatologia , Pessoa de Meia-Idade , Movimento , Contração Muscular , Músculos do Pescoço/fisiopatologia , Placas Oclusais , Avaliação de Processos e Resultados em Cuidados de Saúde , Satisfação do Paciente , Estudos Retrospectivos , Inquéritos e Questionários , Transtornos da Articulação Temporomandibular/etiologia , Dimensão Vertical
11.
J Rheumatol ; 23(11): 1904-11, 1996 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8923364

RESUMO

OBJECTIVE: To investigate the relationship between exposure to silicone (including breast implants) and silica and the development of scleroderma (systemic sclerosis, SSc) among women. METHODS: A population based case-control study was conducted among women in Michigan. 274 confirmed cases of SSc diagnosed between 1985 and 1991 were identified by contacting rheumatologists, hospitals, and a scleroderma support group. These cases and 1184 controls were interviewed by telephone to ascertain past exposures to silicone or silica. RESULTS: Silicone in the form of breast implants was not associated with significantly increased risk of SSc (adjusted odds ratio, 1.30; 95% confidence interval, 0.27 to 6.23). Among 20 other potential silicone exposure surveyed, self-reported exposure to silicone based glues, sealants, and caulks, manufacture or repair of windows or windshields, repairing or frequently using photocopy machines, consumption of simethicone-containing antacids, and implanted medication delivery pumps were significantly associated with SSc. However, blinded assessment of all job and hobby descriptions in terms of their potential for silicone exposure failed to support the first 3 associations, antacid consumption may have been confounded by esophageal dysmotility before the diagnosis of SSc, and other silicone containing device categories (pacemakers, central nervous system shunts, other shunts and catheters) were not significantly associated with SSc. Surgically implanted metallic fixation devices were associated with significantly reduced risk for SSc. No association was detected between SSc and silica dust exposure. CONCLUSION: Consistent with other studies, we found no increased risk of SSc among women with silicone breast implants, equivocal evidence of risk from other silicone exposures, and no evidence of risk from silica exposure.


Assuntos
Implantes de Mama/efeitos adversos , Escleroderma Sistêmico/epidemiologia , Dióxido de Silício/efeitos adversos , Silicones/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Feminino , Humanos , Michigan/epidemiologia , Pessoa de Meia-Idade , Exposição Ocupacional , Razão de Chances , Próteses e Implantes/efeitos adversos , Medição de Risco , Escleroderma Sistêmico/etiologia
13.
N Y State Dent J ; 61(9): 48-53, 1995 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8524518

RESUMO

Temporomandibular disorders (TMD) comprise a group of conditions that can affect the form and function of the temporomandibular joint (TMJ), masticatory muscles and dental apparatus. Proper management of TMD by the dentist requires accurate appraisal of the status of the patient's dentition, TMJ and associated neuromuscular apparatus. Certain predefined standards or parameters of function/dysfunction are accepted by the profession. Electronic instrumentation provides objective measurement of many of these biological phenomena, and thus can be used throughout treatment for critical analyses that monitor and enhance treatment efficacy. A treatment protocol for TMD is presented that uses electronic instrumentation to establish a neuromuscular occlusion.


Assuntos
Eletrônica Médica/instrumentação , Transtornos da Articulação Temporomandibular/terapia , Protocolos Clínicos , Transtornos Craniomandibulares/diagnóstico , Transtornos Craniomandibulares/fisiopatologia , Transtornos Craniomandibulares/terapia , Oclusão Dentária Central , Eletromiografia/instrumentação , Humanos , Registro da Relação Maxilomandibular , Mandíbula/fisiopatologia , Músculos da Mastigação/fisiopatologia , Movimento , Placas Oclusais , Planejamento de Assistência ao Paciente , Som , Articulação Temporomandibular/fisiopatologia , Transtornos da Articulação Temporomandibular/diagnóstico , Transtornos da Articulação Temporomandibular/fisiopatologia , Estimulação Elétrica Nervosa Transcutânea/instrumentação
14.
Infection ; 23 Suppl 1: S21-4, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7782111

RESUMO

A cost-effectiveness study of roxithromycin versus amoxycillin/clavulanic acid using data from a 242 patient multicentre trial in Australia and New Zealand was undertaken in the general practice treatment of infections of the lower respiratory tract (LRTI). Those patients assigned to roxithromycin required on average 1 day less of treatment, significantly fewer extended courses of treatment, and fewer patients experienced side effects considered to be related to the treatment. The cost benefit (difference between the two treatment costs) per clinical success was A$17.04*. By substituting roxithromycin for amoxycillin/clavulanic acid, Australia would save A$ 1.704 million per 100,000 episodes of LRTI. The results demonstrate that savings in direct costs can be achieved by substituting roxithromycin for amoxycillin/clavulanic acid in the treatment of community-acquired LRTI.


Assuntos
Quimioterapia Combinada/uso terapêutico , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/economia , Roxitromicina/economia , Roxitromicina/uso terapêutico , Adolescente , Adulto , Idoso , Amoxicilina/economia , Amoxicilina/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio , Ácidos Clavulânicos/economia , Ácidos Clavulânicos/uso terapêutico , Análise Custo-Benefício , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
15.
Infection ; 23 Suppl 1: S15-20, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7782110

RESUMO

Two hundred and forty-two patients over 16 years of age with community-acquired lower respiratory tract infection (LRTI), matched for age and sex, were randomised to receive either roxithromycin 150 mg b.i.d. or amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for 7 days, with a further 7 days if insufficient response was seen. Clinical efficacy at 7 days was 69% for roxithromycin and 56% for amoxycillin/clavulanic acid (p = 0.05) and at study end it was 91% for both antibiotics. There were fewer second treatment courses in the roxithromycin group (26% vs. 38%, p = 0.04) and a shorter treatment duration (8.29 days vs. 9.34 days, p > 0.05). Twelve patients (9.8%) treated with roxithromycin and 19 (17.1%) treated with amoxycillin/clavulanic acid had adverse effects possibly, or probably, related to the antibiotic. Roxithromycin appears to be a more appropriate choice than amoxycillin/clavulanic acid for the treatment of LRTI in the community given its more appropriate in vitro spectrum, efficacy against most common and atypical pathogens, greater cost-effectiveness, more convenient dosage regimen (b.i.d.), and superior tolerability profile.


Assuntos
Quimioterapia Combinada/uso terapêutico , Infecções Respiratórias/tratamento farmacológico , Roxitromicina/uso terapêutico , Adolescente , Adulto , Idoso , Amoxicilina/administração & dosagem , Amoxicilina/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio , Ácidos Clavulânicos/administração & dosagem , Ácidos Clavulânicos/uso terapêutico , Quimioterapia Combinada/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento
18.
N Y State Dent J ; 60(3): 8-9, 1994 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8170634
19.
J Immunol ; 152(5): 2601-12, 1994 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-7510750

RESUMO

Although Ab-DNA complexes are involved in the pathogenesis of SLE, the mechanism by which anti-DNA recognize their DNA targets remains elusive. We have designed and synthesized small test DNA ligands that model ssDNA and dsDNA determinants commonly recognized by anti-DNA autoantibodies. These ligands were used in DNA footprinting assays to conduct a high resolution epitope-mapping study of anti-ssDNA BV04-01, which is typical of anti-ssDNA expressed in (NZB x NZW)F1 mice. We find that BV04-01 recognizes the ssDNA, but not dsDNA, epitopes presented on the test ligands, and makes specific base and backbone contacts with the DNA. Moreover, BV04-01 binding induces conformational changes in both the single-stranded and duplex region of the ligands. The epitope-mapping data is used in conjunction with computational molecular modeling to construct a three-dimensional model of a BV04-01-ligand complex. The salient aspects of this model are consistent with many features observed in the crystal structure of BV04-01 liganded to d(pT)3. This work extends previous anti-DNA binding studies and attempts to provide a unified approach that draws upon the merits of many precedented experimental methods to assemble three-dimensional structures of anti-DNA-DNA complexes. Analysis of these structures may ultimately help guide the development of molecules designed to inhibit anti-DNA binding in SLE.


Assuntos
Anticorpos Antinucleares/genética , DNA/genética , DNA/imunologia , Animais , Anticorpos Antinucleares/química , Sequência de Bases , Sítios de Ligação , DNA/química , Impressões Digitais de DNA , Eletroquímica , Epitopos/genética , Humanos , Ligantes , Lúpus Eritematoso Sistêmico/genética , Lúpus Eritematoso Sistêmico/imunologia , Camundongos , Modelos Biológicos , Modelos Moleculares , Dados de Sequência Molecular , Conformação de Ácido Nucleico , Conformação Proteica
20.
Cranio ; 11(4): 260-7, 1993 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8118896

RESUMO

Temporomandibular disorders (TMD) afflict millions of men, women and children. Although the management of these disorders has traditionally been the pervue of dentistry, the most common symptoms are otolaryngologic. The involvement of an otolaryngologist was important and necessary in the role of primary diagnostician and as a secondary diagnostician to rule out primary otolaryngologic disease in many of the 2,760 patients evaluated over the past 13 years. In 996 patients referred to the Center for Myofacial Pain/TMJ Therapy from the Otolaryngology Clinic of the New York Eye and Ear Infirmary, 85% complained of ear symptoms, including otalgia (64%), dizziness (42%), and muffling (30%). Sixty percent complained of throat symptoms, while headaches were reported by 81%. In 1,764 private patients evaluated for TMD, 53% were seen and/or referred by an otolaryngologist. The dentist and otolaryngologist must act as a team in recognizing and diagnosing TMD. As many of the symptoms of TMD fall within the pervue of the otolaryngologist, he or she must be cognizant of the clinical presentation of TMD. Likewise, dental practitioners must utilize the services of their medical colleagues to rule out primary otolaryngologic disorders in all patients with suspected TMD.


Assuntos
Otorrinolaringopatias/diagnóstico , Transtornos da Articulação Temporomandibular/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Diagnóstico Diferencial , Dor de Orelha/etiologia , Feminino , Cefaleia/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Otorrinolaringopatias/etiologia , Exame Físico , Prevalência , Estudos Prospectivos , Fatores de Risco , Transtornos da Articulação Temporomandibular/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...